CAS RN: 1423186-80-4
RIP2 kinase inhibitor 1
Product Availability
Choose a grade to view its available package options.
6 package records4 with current stock2 grade groups
| Batch No. | Package | Availability | Warehouse | Inquiry |
| Batchno.20250727 |
1mg / 5mg / 25mg |
Confirm by inquiry |
Shanghai | Inquiry |
| Batch No. | Package | Availability | Warehouse | Inquiry |
| Batchno.20260109 |
100mg |
Out of stock |
| Inquiry |
| Batchno.20260618 |
10mg |
In stock |
Shanghai | Inquiry |
| Batchno.20260201 |
250mg |
Out of stock |
| Inquiry |
| Batchno.20260522 |
25mg |
In stock |
Shanghai | Inquiry |
| Batchno.20250828 |
50mg |
In stock |
Shanghai | Inquiry |
-
Product code:
starshine_CAS1423186-80-4
-
Purity/Analytical Methods:
>99.0%
GET A QUOTE
1423186-80-4 / 2-[4-(1,3-benzothiazol-5-ylamino)-6-tert-butylsulfonylquinazolin-7-yl]oxyethanol
Standard CAS: 1423186-80-4
Multi CAS: No
Basic Information
CAS
1423186-80-4
Multi CAS
No
Molecular Formula
C21H22N4O4S2
Molecular Weight
458.600000
Exact Mass
458.108248
SMILES
CC(C)(C)S(=O)(=O)C1=C(C=C2C(=C1)C(=NC=N2)NC3=CC4=C(C=C3)SC=N4)OCCO
InChI
InChI=1S/C21H22N4O4S2/c1-21(2,3)31(27,28)19-9-14-15(10-17(19)29-7-6-26)22-11-23-20(14)25-13-4-5-18-16(8-13)24-12-30-18/h4-5,8-12,26H,6-7H2,1-3H3,(H,22,23,25)
InChIKey
UHDOJINBFLDQJM-UHFFFAOYSA-N
Computed Properties
Structural Parameters
Heavy atom count
31
Aromatic heavy atom count
19
Fraction Csp3
0.29
Rotatable bonds
6
H-bond acceptors
9
H-bond donors
2
Molar refractivity
121.96
TPSA
114.3
LogP / Solubility
WLOGP
3.93
MLOGP
3.49
XLogP3
3.4
Consensus LogP
3.61
Log S (ESOL)
-5.21
Class (ESOL)
Slightly soluble
Log S (Ali)
-6.16
Class (Ali)
Insoluble
Log S (SILICOS-IT)
-6.62
Class (SILICOS-IT)
Insoluble
ADME
GI absorption
High
BBB permeant
No
P-gp substrate
No
CYP1A2 inhibitor
Yes
CYP2C19 inhibitor
Yes
CYP2C9 inhibitor
No
CYP2D6 inhibitor
Yes
CYP3A4 inhibitor
Yes
Log Kp (skin permeation)
-2.73
Drug-likeness / Medicinal Chemistry
Lipinski
Yes
Ghose
Yes
Veber
Yes
Egan
Yes
Muegge
Yes
Bioavailability score
0.55
Leadlikeness
No
Synthetic Accessibility
3